Abstract
Treatment of systemic-onset juvenile idiopathic arthritis (So-JIA) is challenging, and the efficacy of injectable recombinant human tumor necrosis factor type 1 receptor-antibody fusion protein (etanercept) on So-JIA has been controversial. We retrospectively studied 12 patients with refractory systemic juvenile arthritis treated with etanercept at our hospital in the past 5 years. The 12 patients were divided into a corticosteroid-dependent group (n=7) and an ineffective group (n=5) on the basis of their responses to treatment before the administration of etanercept. Etanercept was added to the treatment without substantially changing the original regimens in general, and doses, and signs of efficacy including alleviation or resolution of symptoms such as high fever, inflammatory arthropathy, eruption rash, hydrohymenitis, as well as changes in the levels of laboratory inflammatory markers such as the white blood cell count, erythrocyte sedimentation rate, levels of C-reactive protein and serum ferritin were recorded. Etanercept was withdrawn after the first dose from one patient in the corticosteroid-dependent group because of a systemic allergic rash, and was also withdrawn from one patient in the ineffective group after 2 m...Continue Reading
References
Oct 23, 1997·Arthritis and Rheumatism·C A Wallace, D D Sherry
Dec 21, 2000·Current Rheumatology Reports·N M WulffraatW Kuis
Aug 21, 2001·Rheumatology·V GerloniF Fantini
Oct 2, 2002·Arthritis and Rheumatism·Kirsten MindenAngela Zink
Apr 11, 2003·Arthritis and Rheumatism·Pierre QuartierAnne-Marie Prieur
Apr 30, 2004·Annals of the Rheumatic Diseases·G HorneffUNKNOWN Paediatric Rheumatology Collaborative Group
Apr 27, 2005·The Journal of Experimental Medicine·Virginia PascualJacques Banchereau
Aug 12, 2005·Current Opinion in Rheumatology·Alexa Adams, Thomas J A Lehman
Mar 6, 2007·Lancet·Angelo Ravelli, Alberto Martini
Mar 25, 2008·Lancet·Shumpei YokotaTadamitsu Kishimoto
Dec 22, 2010·Annals of the Rheumatic Diseases·Pierre QuartierVirginia Pascual
Oct 21, 2011·Expert Opinion on Drug Safety·Giuseppe MurdacaFrancesco Puppo
Dec 21, 2012·The New England Journal of Medicine·Fabrizio De BenedettiUNKNOWN PRCSG
Jan 22, 2013·Expert Opinion on Drug Safety·Giuseppe MurdacaFrancesco Puppo
Mar 19, 2014·The Journal of Rheumatology·Shumpei YokotaTadamitsu Kishimoto
Mar 25, 2014·Expert Opinion on Drug Safety·Giuseppe MurdacaFrancesco Puppo